Q3 2021

Filed Nov 5, 2021 · 10-Q · 36 days after period end · 0001493152-21-027377

Q3 2021 · 10-Q

Revenue—

Net Income

-$3.19M

N/M vs Q3 2020

EPS Diluted

$0.00

— vs Q3 2020

Operating Income-$872,542N/M

Operating Cash Flowderived-$438,854N/M

Same quarter

Metric	Q3 2021	Q3 2020	Q3 2019	Q3 2018
Revenue	—	—	$0.00	$140.76K
Net Income	-$3.19M	-$693.16K	-$1.13M	-$206.98K
EPS Diluted	$0.00	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Kraig Biocraft Laboratories, Inc. · CIK 1413119 · Engraved from SEC EDGAR